Skin manifestations are commonly seen in end stage renal disease (ESRD). Skin involvement in this population can be extensive and dramatically worsen quality of life. Close observation of the skin and nails of ESRD patients by clinicians allows for timely diagnosis and treatment, which ultimately improves quality of life and reduces mortality. In this article we focus on the cutaneous changes most commonly seen in ESRD patients. PubMed/Medline database search was done for published literature on skin manifestations in ESRD patients. All the available literature was reviewed and relevant articles were used to discuss about clinical features, pathogenesis, histology and treatment of each skin disorder in ESRD patients. Most commonly encountered skin manifestations in patients with ESRD are pruritus, xerosis, pigmentation changes, nail changes, perforating disorders, calcifying disorders, bullous dermatoses and nephrogenic systemic fibrosis. Skin manifestations in ESRD can be difficult to treat and multiple comorbidities in this patient population can exacerbate these disorders. Many of the treatment options are experimental with evidence largely derived from the case reports and small clinical trials. More large-scale trials are needed to firmly establish evidence based treatment guidelines. Prompt evaluation and management of these disorders improve morbidity and quality of life in ESRD patients.
INTRODUCTION
Chronic kidney disease (CKD) is a common medical problem in developed countries. More than 661,000 people in the United States have end stage renal disease (ESRD). 1 Although the incidence has plateaued over recent years, the prevalence has been continually increasing likely due to improved disease management and decreased mortality. 1 Kidney disease affects many organ systems, but the focus of this review will be on the dermatological manifestations of ESRD. Cutaneous manifestations may arise before or after a patient starts dialysis. Skin involvement can be extensive and often significantly impact the individual's quality of life. A study by Pico et al. found that of 102 ESRD patients, all had at least one form of skin alteration including alterations in cutaneous pigmentation, half-and-half nails, pruritus, and keratotic pits among others. 2 It is important for clinicians diagnosis and treatment leads to improved quality of life and decreased mortality for ESRD patients. The aim of this review is to discuss the pathogenesis, clinical features, and treatment options for various dermatological manifestations in CKD. The dermatological disorders caused by ESRD can be broadly categorized as nonspecific and specific ( Figure 1 ). Nonspecific changes include pruritus, xerosis, pigmentation disorders, and half-and-half nails (Lindsay's nails). Specific changes include acquired perforating disorders, bullous dermatoses, calcifying disorders, and nephrogenic systemic fibrosis. Clinical manifestations, pathophysiology, and management of dermatologic disorders in ESRD are summarized in Table 1 .
NONSPECIFIC
Case: A 57-year-old African American male presented with a 5 month history of dry and thickened skin. He had a past medical history of CKD stage IV secondary to type 2 diabetes mellitus and had been on hemodialysis three times weekly for 3 years. On physical exam, he was noted to have thickened skin with an overlying scale predominately on the upper and lower extremities. The skin had a grayish color and there were numerous fissures.
Diagnosis: Xerosis.
Uremic pruritus
Pruritus is one of the most common complaints associated with ESRD. Pruritus is present in anywhere from 40% to 90% of patients with ESRD, which reflects its subjective nature. 3 Its incidence is seemingly independent of sex, age, race, and etiology of kidney failure. 4, 5 There are many hypotheses, but the pathophysiology of pruritus remains unknown. Secondary hyperparathyroidism is proposed as a cause of pruritus and in fact, there are reports that support resolution of pruritus following parathyroidectomy. 6 However, it has also been shown that circulating levels of parathyroid hormone do not correlate with degree of itching. 7 Uremic pruritus may be localized or generalized. The frequency, severity, and clinical characteristics vary widely and range from mildly irritating to severely debilitating. 8 Physical cutaneous changes my also coincide with the onset of pruritus. These changes include linear streaks, skin xerosis, lichenification keratosis pilaris, eczema, and prurigo nodules. 9 Prurigo nodules present as symmetrically distributed hyperkeratotic nodules with erosion. They develop from continual scratching in patients with pruritus as a result of neuronal sensitization to itch and subsequent development of an "itch-scratch cycle." 10 A study of patients with long standing pruritus secondary to chronic renal failure by Bohme et al. found that over half of these patients exhibited prurigo nodules. 11 It is important to recognize that some patients with CKD may have concurrent uremic pruritus and neuropathic pruritus. While the mechanism of neuropathic pruritus is not fully understood, the proposed mechanism suggests that it results from damage to nerve fibers at any point along the afferent pathway of the nervous system. Signs of neuropathic itch include complaints of burning, parasthesia, tingling, and stinging. 12 Despite many advances in the management of ESRD, the treatment of uremic pruritus remains a challenging clinical problem. While there are many treatment options, they are often ineffective and not firmly evidence based as they are largely derived from case reports and small clinical trials. 13 When a patient develops pruritus, it is important to evaluate and optimize their dialysis dose to ensure adequate dialysis. A study by Hiroshige et al. showed that hemodialysis patients who were aggressively dialyzed had significant reductions in pruritus severity, 14 thus when patients are adequately dialyzed, more aggressive dialysis can be tried on a caseby-case basis. Definitive treatment for patients with severe uremic pruritus remains kidney transplantation in patients with ESRD 13 though only a small subset of patients qualify for transplant.
Topical treatments are first-line therapy in addition to optimization of dialysis. These are especially preferred for patients with extremely dry skin although the response is variable. 15 One study demonstrated that emollients with high water content, such as gamma-linolenic acid, have a therapeutic effect significant to placebo and may act through an anti-inflammatory or immunoregulatory effect. 16 Other topical treatments include capsaicin, pramoxine lotion, and tacrolimus ointment. The mechanism of action of capsaicin is thought to be through depletion of substance P from peripheral neurons thus blocking transmission of pain and pruritus signals. 17 Capsaicin demonstrated statistically significant improvement in pruritus symptoms compared to placebo in two studies. 17, 18 The most common adverse effects include localized burning, stinging and redness, therefore, capsaicin should only be considered in patients with a small affected area. 19 A single study on pramoxine lotion determined there is a statistically significant benefit compared to a control lotion. 20 The data supporting tacrolimus still remains unclear. Pauli-Magnus et al. demonstrated a short-term efficacy of 0.03% tacrolimus ointment over 7 days for three cases, 21 however, these results were unable to be confirmed in subsequent studies by Duque et al. when using a higher concentration of 0.1% over 4 weeks 22 or by Ghorbani et al. using pimecrolimus. 23 Before it can be considered for common use, the effectiveness of tacrolimus needs further testing in uremic pruritus. It is also important to keep in mind the serious side effects as tacrolimus is a potential carcinogen. Systemic therapy for pruritus includes gabapentin, antihistamines, mast cell stabilizers, montelukast, thalidomide, activated charcoal, and phototherapy. Gabapentin is an anticonvulsant that has been used in the management of chronic pain and diabetic neuropathy. Neuropathic pain and pruritus are thought to share common pathogenic mechanisms thus gabapentin has become first-line pharmacologic therapy for uremic pruritus. 13 A systemic review of uremic pruritus treatments found a statistically significant benefit to using gabapentin or pregabalin compared to placebo. 19 The adverse effects of anticonvulsants include drowsiness and dizziness. Histamine has been implicated in the pathogenesis of uremic pruritus because elevated histamine levels have been demonstrated in ESRD. 24, 25 Antihistamines are commonly prescribed but consistently have not been shown to improve symptoms of itch in ESRD. Additionally, the side effect of sedation can pose problems for most patients with ESRD. Mast cell stabilizers, such as cromolyn sodium and nicotinamide, work by preventing the degranulation of mast cells. Cromolyn sodium has been compared to placebo in two studies and showed a significant reduction in pruritus intensity. 26, 27 Nicotinamide was studied in one trial and was not found to be more effective than placebo. 28 Only cromolyn sodium was noted to have adverse effects including a burning sensation and flatulence. 19 Montelukast, a leukotriene receptor antagonist, was found to significantly improve pruritus compared to placebo in one study. 29 There were no adverse effects associated with montelukast. Thalidomide holds promise but more studies are needed. A single crossover study conducted by Silva et al. showed statistically significant improvement in pruritus for 50% of patients. 30 Thalidomide is contraindicated in women who menstruate due to the drug's teratogenic effects. 31 The exact mechanism of action of activated charcoal is unknown but it has been suggested to act by binding pruritogens in the intestinal lumen thus preventing their absorption and action. 31 Activated charcoal has shown efficacy in two small trials. 32, 33 Additionally, this treatment option is cost effective with limited side effects. Lastly, the role of phototherapy in uremic pruritus treatment has also been examined. Two studies comparing broadband UV-B to UV-A demonstrated a significant benefit to UV-B therapy. 34, 35 However, there is no statistically significant benefit to using narrow-band UV-B compared to UV-A. 36 The adverse effects of short-term usage include sunburn and tanning, while long term usage may cause photoaging and skin cancers. 37, 38 Other investigations such as kappa opioid agonists, μ-opioid receptor antagonists, cholestyramine, and erythropoietin have been used with mixed results. The k-opioid receptor agonist nalfurafine hydrochloride was examined in two studies. In one study, nalfurarine hydrochloride was found to have a statistically significant benefit over placebo. 39 The second study found no significant benefit to using nalfuraine hydrochloride infusion. 40 The most common adverse effects include headache, nausea, and insomnia. 19 CR845 is a peripherally restricted k-opioid receptor agonist that has been shown to antagonize pruritus in a dose-dependent manner. 41 Cara Therapeutics has initiated the Phase III clinical trial. Nalbuphine, another novel therapy for pruritus, is a k-opioid and μ-opioid receptor antagonist. A multicenter, randomized, double blind, placebo-controlled trial of 373 hemodialysis patients with moderate or severe uremic pruritus found that nalbuphine significantly reduced itching intensity among hemodialysis patients. 42 In two studies naltrexone, a μ-opioid receptor antagonist, yielded mixed results. One study showed statistically significant benefit over placebo 43 while the other did not. 44 In a single study comparing cholestyramine to placebo, 80% of patients had full or considerable relief whereas 20% responded similarly to placebo. 45 The study did not note if there was a statistically significant difference between the two groups. Erythropoietin has been used with mixed results and more clinical trials are needed.
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Xerosis
Xerosis is common in patients with ESRD. The prevalence is estimated between 50% and 85% of the cases, although it is more common in those that have not yet started dialysis. 49 It presents as dry and thickened skin with ichthyosiform scaling predominately on the trunk and extensor surfaces of the extremities (Figure 2) . 31, 50 While xerosis is commonly accompanied by pruritus, there is no clear correlation between the degree of xerosis and pruritus. There have been several mechanisms proposed but the pathogenesis of xerosis remains unclear. The leading theory proposes that xerosis is caused by atrophy of sweat and sebaceous glands leading to dehydration of the stratum corneum as well as reduced sebum and sweat production. Treatment involves limiting hand washing and showering, daily emollients, particularly those with a high water content, and avoidance of skin irritants.
24,50,51
Pigmentation disorders
There are a wide variety of pigmentation disorders that are seen in ESRD. Changes related to color include pallor, yellowing of the skin, gray-brown skin, hyperpigmentation and ecchymoses. These studies have shown that the degree of pigmentation is directory correlated with duration on dialysis. 52 Pallor is attributed to anemia of chronic disease and erythropoietin deficiency and is seen in approximately 40% of patients. 53, 54 Yellowing of the skin is caused by retained carotene, urobilinogen and other fatsoluble pigments in the dermis and subcutaneous tissue while gray-brown discoloration is due to hemosiderin deposits from chronic transfusions. 55 Hyperpigmentation results from increased melanocyte stimulating hormone (MSH), which causes increased melanin and worsens with sun exposure. Hyperpigmentation is seen in approximately 20% of patients. 53, 54 Ecchymoses are extremely common due to platelet dysfunction secondary to elevated urea and creatinine. 50 Elevated levels of these substances can induce changes in platelets and alter platelet aggregation. 55 Pallor may improve with erythropoietin treatment and correction of anemia. 50 Currently, there are not any first line treatments for hemosiderin deposits, however, case studies demonstrate successful treatment of hemosiderin containing hyperpigmentation with the Q-Switched (QS) 650-nm Nd:YAG laser, 56 the 50-ns QS 755-nm alexandrite laser, 56, 57 the QS ruby laser 58 and the 700-picosecond alexandrite laser. 56 This therapy shows promise but needs further testing. Hyperpigmentation can be improved by daily sunscreen use in addition to sun protection. 50 Optimization of dialysis can improve and reduce the development of ecchymoses. There is no treatment available for yellowing of the skin.
Half-and-half nails (Lindsay's nails)
In half-and-half nails, also known as Lindsay's nails, the proximal one half to two thirds of the nail is white while the distal portion has discoloration that may range from pink to brown. This is seen in approximately 20% of patients with ESRD. 50 The exact mechanism of half-andhalf nails is unknown. One hypothesis suggests that there is an increased tissue concentration of MSH. 50 Another is that they are due to edema of the nail bed. 31 There is 
Acquired perforating disorder
Acquired perforating disorders include Kyrle's disease, reactive perforating collagenosis, and perforating folliculitis. They are a group of disorders characterized by elimination of altered dermal structures such as collagen, keratin, and elastic fibers through the epidermis (Figure 3 ). Perforating disorders are frequently found in dialysis patients with diabetes mellitus as well as in African Americans. 31 They typically develop after the initiation of dialysis and are seen in approximately 2%-11% of dialysis patients. 59, 60 The pathophysiology is unknown.
Kyrle's disease occurs in anywhere from 10% to 21% of ESRD patients undergoing hemodialysis. 61, 62 The lesions in Kyrle's disease appear as 2-8 mm domeshaped papules with a keratotic plug distributed among the trunk buttocks and proximal extremities. Papules may coalesce into plaques often with a linear pattern and can be accompanied by intense pruritus. Histologically, lesions appear as parakeratotic plugs with basophilic material and epidermal depression with adjacent vacuolated epidermal cells. 50 Reactive perforating collagenosis (RPC) is a rare genodermatosis of autosomal dominant or recessive inheritance characterized by transdermal elimination of altered collagen. The inherited forms of RPC present in childhood and are often triggered by trauma, folliculitis and exposure to cold weather. 55 The pathophysiology is unknown although it is postulated that it is triggered by superficial trauma in genetically susceptible individuals, which leads to necrobiosis of collagen in the dermal papillae that is subsequently eliminated through the epidermis. 63 RPC may be acquired in adulthood due to diabetes or chronic renal disease. RPC presents as brownish or pinkish papules or plaques that can be keratotic, umbilicated, nodular or verrucous, and are often accompanied by pruritus. 55 They are distributed in exposed areas such as the face and upper and lower extremities with minor involvement of the trunk. 55 The papules become umbillicated over a span of 3-5 weeks and subsequently undergo spontaneous regressive over 6-8 weeks leaving a scar. 64 Lesions are often present in varying stages of development.
In perforating folliculitis, degenerated follicular units with or without collagen and elastic fibers are eliminated through the epidermis. 65 It is the least common of the perforating disorders. Perforating folliculitis appears similarly-both clinically and histologically-to the other perforating disorders with the addition of follicular involvement. The treatment regimen for perforating disorders is variable. The goal of treatment is often relief of pruritus. Patients may respond to topical or oral retinoids and vitamin A, oral antihistamines, topical steroids, intralesional steroid injections, Psoralen Ultra Violet-A (PUVA), Narrow Band UV-B (NBUVB), and allopurinol. 31, 59, [65] [66] [67] Cryotherapy and keratolytics have been efficacious in several case reports, particularly for Kyrle's disease. 68 Case: A 60-year-old obese Caucasian female with a history of hypertension, type 2 diabetes mellitus and ESRD requiring hemodialysis four times weekly presented with extremely tender lesions of 3 weeks duration. Bilaterally on the medial thighs were firm violaceous plaques with a reticular pattern. Laboratory tests revealed: BUN 74 mg/dL, creatinine 13.7 mg/dL, serum parathyroid hormone level 163 pg/mL, serum calcium 8.3 mg/dL, serum phosphorus of 4.1 mg/dL, and serum albumin of 3.1 g/ dL. A skin biopsy demonstrated calcification of dermal arterioles, fibrosis of the dermis and subcutaneous tissue and a scant inflammatory infiltrate.
Diagnosis: Calciphylaxis.
Calcifying disorders
Metastatic calcification is the process in which excess calcium salts are deposited into cutaneous or subcutaneous tissues. CKD results in hyperphosphatemia from decreased excretion of phorphorus and hypocalcimia from decreased absorption of calcium. This imbalance triggers secondary hyperparathyroidism that raises parathyroid hormone levels and causes mobilization of calcium and phosphate from the bone into the serum. 69, 70 When these minerals reach their solubility, metastatic calcification, calcinosis cutis, and calciphylaxis may occur. Calcium deposits may occur in gastric mucosa, vascular walls, lung, kidneys, and subcutaneous tissue. 71 Metastatic calcification presents as calcinosis cutis or calciphylaxis in patients with ESRD.
Calcinosis cutis, also known as cutaneous calcinosis and benign nodular calcification, is the deposition of insoluble calcium salts in the dermis and subcutaneous tissue without tissue necrosis. The annual incidence is roughly 1% of patients with ESRD on maintenance dialysis. 72 Calcinosis cutis is characterized clinically by yellow to white stony papules, nodules, and plaques commonly distributed in the periarticular regions and fingertips (Figure 4) . Lesions of the fingertips are often very painful while periarticular lesions are typically painless unless joint mobility is affected. 73 There may be elimination of material through the dermis. Histologically, calcium appears as homogeneous blue material in the superficial dermis as well as globular deposits in the subcutaneous tissue that is best visualized with H&E staining. 68, 74 Normalization of calcium and phosphorus levels can lead to regression of the lesions, 68, 74 which can be achieved by phosphate binders, reduction of dietary phosphate, calcium mimetic drugs such as cinacalcet, or surgical parathyroidectomy. 68, 72, 75 Calciphylaxis, also known as calcific uremic arteriolopathy, is a rare and life-threatening disease seen in patients with severe renal impairment on dialysis and can also be seen in secondary and tertiary hyperparathyroidism and renal transplant among other diseases. After examining data from a nationwide registry in Germany, Brandenburg et al. suggested that the annual incidence of calciphylaxis is approximately 0.04%, much lower than previously thought. 76 The prevalence is 1%-4% in those with ESRD and the mortality rate is 60%-80%. 50 Roughly 30% of cases are reported in kidney transplant patients. 68 Calciphylaxis is characterized by thrombosis of calcified small and medium sized arteries and arterioles of primarily the dermis and subcutaneous fat. 50 The pathogenesis is unknown but is thought to be multifactorial. Metabolic factors such as calcium and phosphate levels, parathyroid regulation, systemic inflammation, oxidative stress, and endothelial injury have been implicated in the pathogenesis. 50 A study by Dobry et al. showed an association between hypercoagulable conditions and calciphylaxs in patients with renal disease. 77 Clinically, calciphylaxis presents as erythematous firm plaques or nodules that become progressively more painful, pruritic and violaceous over days to weeks. This reticular purple discoloration may resemble livedo reticularis. They are most commonly distributed symmetrically and bilaterally over the lower extremities but may extend over many body surfaces. Lesions are frequently found overlying thick adipose tissue, areas where skin surfaces are in contact or sites of trauma. 31 Lesions frequently progress to become necrotic with eschar formation predisposing to infection. Histologically, there may be calcification of small and medium sized arteries with fibrosis in the dermis and subcutaneous tissue with little to no inflammatory infiltrate. 50 There may also be fibrin thrombi within arteries, epidermal ulceration, and ischemic necrosis of the epidermis, dermis, and subcutaneous tissue. 59, 78 Differential diagnoses include atherosclerotic vascular disease, cholesterol embolization, nephrogenic systemic fibrosis, oxalate vasculopathy, purpura fulminans, vasculitis, and warfarin necrosis. 79 Treatment is mainly aimed at controlling mineral metabolism parameters, most importantly calcium and phosphorus. Cinacalcet acts as a calcium mimetic that increases the sensitively of the parathyroid gland cell to calcium. It has been shown to reduce the rate of parathyroidectomy by more than half. 80 Treatment should be discontinued when parathyroid hormone (PTH) levels normalize to prevent renal osteodystrophy. 81 If the disease is still uncontrolled, patients may undergo parathyroidectoy. Studies show that patients who undergo early total or subtotal parathyroidectomy have a longer survival compared to those who do not undergo the procedure. 55, 82 Increased frequency and duration of dialysis with low calcium dialysate controls electrolyte levels and improves this condition. 82 Bisphosphonates such as etidronate and pamidronate have been effective, resulting in pain relief within days and resolution of lesions within weeks. [82] [83] [84] [85] Sodium thiosulfate may act by displacing calcium from calcium phosphorus, forming calcium thiosulfate, which is more soluble and can be excreted through haemodialysis or by the kidneys. 82 It has achieved pain relief within days and wound healing within 8 weeks. 86 It is important to monitor for the side effect of metabolic acidosis when using this drug. 87 Hyperbaric oxygen has been used with limited success in wound management and cases refractory to other treatment methods. 88 The mechanism is believed to be improvement of angiogenesis and phagocytosis with inhibition of bacterial growth and reduction of local tissue edema. 55 Additionally, management of lesions may require debridement, systemic antibiotics, biological or hydrocoloid dressings, and skin grafting. 55 Case: A 55-year-old woman with ESRD requiring hemodialysis twice weekly presented complaining of intermittent blisters on her hands of sixth months duration that were exacerbated by sun exposure. On the bilateral dorsal hands are numerous pink to red vesicles and bullae with areas of erosion and scarring. Plasma porphyrin levels were as follows: total porphyrins 59.2 mcg/dL and uroporphyrin 42.5 mcg/dL. Laboratory results revealed: hemoglobin 9.3 g/dL and ferratin 345.1 ng/mL.
Diagnosis: Porphyria cutanea tarda.
Bullous dermatoses
The two bullous disorders seen in those with renal impairment are porphyria cutanea tarda, also known as chronic hepatic porphyria, and pseudoporphyria. The prevalence of these disorders in hemodialysis patients is estimated to range from 1.2% to 18%. 72 Porphyria cuntanea tarda results from an abnormality during heme biosynthesis caused by a deficiency of the enzyme uroporphorynogen decarboxylase and can be congenital or acquired. Clinical manifestations are not seen until the enzyme reaches 30% activity. 68 It is characterized by multiple painful vesicles, bullae and erosions on the hands and extensor surfaces that are exacerbated by sun exposure ( Figure 5 ). Scarring, milia, skin fragility to minor trauma, post sun exposure hyperpigmentation, sclerodermoid changes, and hypertrichosis have been observed. 55 Histology is characterized by subepidermal clefts and blistering with little to no inflammatory infiltrate. 55 Vessel walls may be thickened. Direct immunofluorescence staining reveals linear and granular deposits of immunoglobulin G and C3 in the dermal-epidermal junction and perivascularly. 54, 68 Various factors have been implicated in the pathogenesis of porphyria cutanea tarda (PCT). Azotemia is thought to reduce the activity of uroporphyrinogen decarboxylase. 49 Additionally, renal failure causes poor clearance of uroporphyrins leading to higher plasma levels. 54 PCT is seen in patients with hemodialysis because porphryrins complex with high molecular weight proteins, which makes it difficult for them to be removed by dialysis. 72 The major risk factors associated with PCT include alcohol, iron, estrogens, hemochromatosis, and viral infections including hepatitis B, hepatitis C, and HIV. 68, 89 Treatment of PCT includes avoiding triggers such as alcohol, hepatotoxic medications, and sun exposure as well as using sunscreen, particularly zinc oxide, and titanium oxide-based sunscreen. 50, 82 Decreasing iron overload is effective for symptom management and can be achieved by a combination of erythropoiesis stimulating agents and small volume phlebotomy (50-100 mL once or twice weekly) to decrease hepatic iron stores. 50 The mechanism of iron therapy is twofold because iron induces the enzyme 5-aminolevulinate synthase, which suppresses uroporphyrinogen decarboxylase and because iron increases conversion of uroporphyrinogen into porphyrins. 82 Additionally, iron chelators such as deferoxamine have demonstrated some therapeutic success but they come at the cost of side effects. 55 Chloroquine increases the solubility of porphyrins and facilitates urinary excretion, however, it is of not benefit in anuric patients. 55 In refractory cases of PCT, two plasma exchange treatments, separated by 48 hours may be effective, 82 however renal transplantation is the only definitive treatment. 90 Pseudoporphyria presents similarly to PCT both clinically and histologically, however, there are no clear porphyrin abnormalities and hypertrichotic and sclerodermoid changes are not usually observed. 55, 91 Although the exact pathophysiology in ESRD patients is not known, it is commonly associated with medications including furosemide, nalidixic acid, tetracycline, naproxen, cyclooxygenase inhibitors, and amiodarone, as well as with the excessive use of tanning beds. 55 Treatment of pseudoporphyria involves stopping medications that are known triggers as well as sun avoidance and sun protection. 50 N-acetylcysteine, a glutathione precursor that increases antioxidant activity and clearing of free radicals has demonstrated efficacy in several case reports. 82, 92 Case: A 51-year-old male presented with a 3-week history of progressive pain, pruritus and swelling in his feet accompanied by a feeling of "tightness." The patient had a past medcal history of ESRD secondary to uncontrolled type 2 diabetes mellitus. Four weeks ago the patient had undergone magnetic resonance imaging for a suspected intracranial tumor. Physical examination revealed bilateral sclerosis of the distal feet with diffuse keratotic white papules coalescing into plaques and cobblestoning. There were overlying areas of erythema and hyperpigmentation. Skin biopsy revealed a thickened dermis, dermal collagen bundles arranged haphazardly, proliferation of dermal spindle cells that stain positive for CD34 and procollogen I and interstitial mucin deposition. Within the deep dermis were scattered histiocytes and multinucleated giant cells. Fibrosis extended from the dermis into the subcutaneous fat.
Diagnosis: Nephrogenic systemic fibrosis.
Nephrogenic systemic fibrosis
Nephrogenic systemic fibrosis (NSF), formerly known as fibrotic uremic dermopathy, is a disorder most commonly caused by gadolinium-based contrast agents (GBCAs) in those with renal disease. It is seen almost exclusively in those with renal insufficiency with a GFR < 30 mL/min due to their decreased ability to renally clear the GBCAs. 50 Normally, GBCAs are almost exclusively excreted by the kidneys with over 95% of the administered dose cleared within 24 hours. 93 The length of the half-life directory correlates to the degree of glomerular filtration rate (GFR) impairment. 82 NSF affects men and women equally and there are currently no known associations with race or etiology of renal insufficiency. 50 The majority of cases are seen in middle-aged adults, with an average age at onset of 51 years. 94 The increased half-life in those with renal insufficiency allows the GBCAs to dissociate into toxic free ions that are subsequently deposited into tissues. It has been shown that once in tissue, gadolinium is phagocytized by macrophages, which may lead to the recruitment and/or activation of circulating fibrocytes that subsequently differentiate into fibroblasts. [95] [96] [97] NSF has rarely been diagnosed in those who have not received GBCAs. It has developed in the setting of thrombophilia, surgical procedures, and liver disease. The association of NSF with thrombosis and surgical procedures might indicate that inflammation plays a role in its development. 98 NSF has arisen in the setting of chronic liver disease including hepatitis B and C and hepatorenal syndrome and has also developing during the peri-transplant period following liver transplantation.
Clinically, NSF involves increased deposition of collagen within tissues resulting in skin thickening and hardening as well as fibrosis that may involve other organs. 55 Skin manifestations include hyperpigmented skin with hard papules, plaques, or nodules that are symmetrically distributed on the lower extremities and occasionally on the upper extremities and trunk and rarely on the face. The lesions are severely painful and may be accompanied by edema, erythema, and induration of the skin. 50 As the disease progresses, flexion contractures may occur in the joints resulting in increasingly limited mobility that may ultimately cause patients to become wheelchair-bound. 31 Skin biopsy is required for definitive diagnosis. Skin biopsy will demonstrate increased dermal collagen spindle cells arranged haphazardly that stain positive for CD34 and procollagen 1, as well as increased numbers of fibroblast-like cells and mucin deposition. 82, 100 However, in contrast to other fibrotic skin disorders, there are only minimal inflammatory cells in the skin in NSF. 31 Despite having discrete pathologic processes, NSF and calciphylaxis can occur simultaneously and may be found within the same lesion on histology. 101, 102 Deep excisional biopsy is recommended to rule out concomitant calciphyaxis in patients clinically presenting with NSF due to the adverse outcomes associated with calciphylaxis. 101 Prevention of NSF can be accomplished by dialysis. Two 4-hour hemodialysis sessions are needed to remove the contrast and should be performed in the first 3 hours. 103 Rehabilitation can help prevent or slow disease progression of the joints while swimming and massage can improve symptoms. 104 The only successful treatment for NSF is improvement in renal function via transplantation, which has demonstrated improvement in 54% of patients and full remission in some cases, but even this procedure does not always guarantee resolution of disease and associated symptoms. 31, 82 The success of other proposed treatment options have been mostly anecdotal in case reports and require further investigation. Topical and systemic corticosteroids have demonstrated some efficacy, but many adverse effects are observed. 91 Extracorporeal photopheresis has been proven to be effective for softening of injuries and improving mobility. 86 It is an immunomodulatory treatment that induces lymphocyte apoptosis via UV light that slows down synthesis and deposition of collagen. 86 Intravenous immunoglobulin G is another immunomodulatory agent that is thought to induce anti-inflammatory cytokines and has been successful anecdotally. 105 Plasmapharesis acts by reducing levels of transforming growth factor beta. Baron et al. used this technique in kidney transplant patients, which resulted in improvement in skin lesions and joint mobility. 106 Imatinib is a tyrosine kinase inhibitor that acts by inhibiting platelet-derived growth factor and c-Abl kinase, thus inhibiting the synthesis of collagen and fibronectin by dermal fibroblasts. 82 Imatinib has been shown to achieve moderate success in softening and decreasing the size of lesions and improving pain, but has shown mixed results in improving mobility. [107] [108] [109] Alefacept has been shown to be effective in treating graft-vs.-host disease, which shares sclerodermoid features with NSF. It acts by inhibiting the activation of CD4+/CD8+ T lymphocytes and inducing apoptosis of memory effector T lymphocytes. Alefacept was shown to improve the skin manifestations of three patients in a single case series with NSF. 110 Sirolimus has demonstrated a marked reduction in edema of the lower limbs as well as an improvement in joint mobility of both hands and ankles in a gadolinium naïve patient. 111 In a single case report, sodium thiosulfate was shown to increase joint mobility and skin softening in addition to decreasing pain. 112, 113 Additional treatment options that have been tried without significant improvement include intralesional interferon-α, intralesional methotrexate, 114 and monthly intravenous cyclophosphamide. 115 Fortunately, there has been a reduction in the incidence of NSF over the past few years due to increased awareness and routine screening of patients with renal disease who undergo imaging with GBCAs. 94 
CONCLUSION
Skin manifestations are common in ESRD and can be difficult to treat clinically. Moreover, multiple comorbidities in this patient population can exacerbate these disorders. These skin disorders are often difficult to control, have a significant impact on the patient's quality of life and can even be life threatening. In recent years, there have been many advances, however, much more research is needed. Prompt evaluation and management of these disorders improves morbidity and quality of life in ESRD patients.
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